Slideshow

New Products: Laser line offers dusting, fragmentation, ablation capabilities

Also read about expansions to an intermittent catheter line, a new radiofrequency treatment for improving local vaginal circulation, an app for men navigating fertility challenges, and more.

Olympus EMPOWER

Laser line offers dusting, fragmentation, ablation capabilities

Olympus has launched its EMPOWER laser portfolio line, which offers a range of capabilities in Ho:YAG lithotripsy, including dusting, fragmentation, and soft tissue ablation. The EMPOWER system offers physicians and hospitals several choices in mode, power, and frequency. Its Stabilization mode reduces retropulsion effect, meaning that it produces a vapor tunnel bubble path to the stone to stabilize the stone and limit retropulsion. Olympus says the high-power platform offers greater efficiency and higher hertz than competitive systems with similar power offerings and also features customizable user settings.

 

Related Videos
Vanita Gaglani, RPT, answers a question during a video interview
Vanita Gaglani, RPT, discusses books on post-prostatectomy incontinence and prostatitis
Diet and interstitial cystitis: A urologist’s view
Diet and interstitial cystitis: A urologist’s view
Adam Lorentz, MD, on predictions for future advances in robotics
Adam Lorentz, MD, on predictions for future advances in robotics
J. Quentin Clemens, MD, MSCI, answers a question during a video interview
J. Quentin Clemens, MD, on tailoring interstitial cystitis treatment
Jeffrey A. Albaugh, PhD, APRN, CUCNS, answers a question during a Zoom video interview
Jeffrey A. Albaugh, PhD, APRN, CUCNS, on editing the second edition of SUNA’s Core Curriculum
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Top 10 Urology Times videos of 2024
Ronney Abaza, MD, on robotic surgery at ultralow pressures
Ronney Abaza, MD, on robotic surgery at ultralow pressures
Ronney Abaza, MD, on maximizing the benefits of minimally invasive robotic surgery
Ronney Abaza, MD, on maximizing the benefits of minimally invasive robotic surgery
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Expert: Catheter reprocessing device has potential to be “game changer”
A. Lenore Ackerman, MD, PhD, answers a question during a Zoom video interview
Dr. A. Lenore Ackerman on sulopenem and the UTI treatment landscape
Related Content
Novel drug delivery approach shows promise for UTI
March 12th 2025

Novel drug delivery approach shows promise for UTI

Hannah Clarke
The method involves local delivery of the antibiotic gentamicin directly into the bladder tissue.
Key updates from the AUA/ASRM male infertility guideline amendment
September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff
In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.
FDA grants 510(k) clearance to RELIEF stent for vesicoureteral reflux
January 14th 2025

FDA grants 510(k) clearance to RELIEF stent for vesicoureteral reflux

Hannah Clarke
In a recent study of the RELIEF stent, 95% of patients showed no VUR following stent placement.
Destigmatizing Urology: Dr. Winter discusses STDs/STIs
March 22nd 2022

Destigmatizing Urology: Dr. Winter discusses STDs/STIs

Urology Times staff
“We need to just approach STIs as the medical conditions they are because until we do, and until we take those stigmas away, people will truly have resistance to discussing it, hesitance to discussing it, and resistance to diagnosis and intervention,” says Ashley Winter, MD.
FDA logo
January 1st 2025

2024 Urology Times pipeline report

Jason M. Broderick Hannah Clarke Brittany Lovely
Catch up on all the notable drug and device approvals in urology over the past year.
ELIMINATE trial: uUTI regimen demonstrates initial tolerability, efficacy
November 1st 2024

ELIMINATE trial: uUTI regimen demonstrates initial tolerability, efficacy

Hannah Clarke
A rapid reduction in E coli in the urine was observed among 10 of 16 evaluable patients at 4 hours following the first treatment.
© 2025 MJH Life Sciences

All rights reserved.